Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc., a Delaware corporation, on April 30, 2026. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the clinical advancement of the Company's lead asset.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure event rather than financial performance data.
Material Changes and Events
- Clinical Presentation: On April 30, 2026, the Company announced that the mechanism of action and clinical advancement of its first oral protease inhibitor, CDI-988, were featured in an oral presentation.
- Event Details: The presentation occurred at the 39th International Conference on Antiviral Research (ICAR 2026) held in Prague, Czech Republic.
- Disclosure Status: The information, including the press release (Exhibit 99.1), is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclaimer regarding the non-filed status of the press release. The primary focus is the dissemination of scientific data regarding CDI-988.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data points regarding CDI-988.
- Confirm the details of the oral presentation at ICAR 2026 to understand the specific mechanism of action discussed.
- Review subsequent filings for any financial impact or strategic shifts resulting from this clinical update.